全文获取类型
收费全文 | 23654篇 |
免费 | 1287篇 |
国内免费 | 134篇 |
专业分类
耳鼻咽喉 | 150篇 |
儿科学 | 587篇 |
妇产科学 | 390篇 |
基础医学 | 2921篇 |
口腔科学 | 737篇 |
临床医学 | 1590篇 |
内科学 | 6057篇 |
皮肤病学 | 473篇 |
神经病学 | 2091篇 |
特种医学 | 778篇 |
外科学 | 3796篇 |
综合类 | 122篇 |
一般理论 | 1篇 |
预防医学 | 601篇 |
眼科学 | 353篇 |
药学 | 1746篇 |
中国医学 | 29篇 |
肿瘤学 | 2653篇 |
出版年
2023年 | 120篇 |
2021年 | 385篇 |
2020年 | 239篇 |
2019年 | 317篇 |
2018年 | 458篇 |
2017年 | 324篇 |
2016年 | 384篇 |
2015年 | 450篇 |
2014年 | 542篇 |
2013年 | 679篇 |
2012年 | 1039篇 |
2011年 | 1145篇 |
2010年 | 653篇 |
2009年 | 549篇 |
2008年 | 988篇 |
2007年 | 1145篇 |
2006年 | 1068篇 |
2005年 | 1098篇 |
2004年 | 1047篇 |
2003年 | 987篇 |
2002年 | 1003篇 |
2001年 | 960篇 |
2000年 | 927篇 |
1999年 | 868篇 |
1998年 | 282篇 |
1997年 | 227篇 |
1996年 | 251篇 |
1995年 | 172篇 |
1994年 | 164篇 |
1993年 | 150篇 |
1992年 | 541篇 |
1991年 | 506篇 |
1990年 | 515篇 |
1989年 | 466篇 |
1988年 | 441篇 |
1987年 | 438篇 |
1986年 | 382篇 |
1985年 | 395篇 |
1984年 | 281篇 |
1983年 | 194篇 |
1982年 | 115篇 |
1979年 | 217篇 |
1978年 | 143篇 |
1977年 | 141篇 |
1974年 | 130篇 |
1971年 | 136篇 |
1970年 | 136篇 |
1969年 | 128篇 |
1968年 | 141篇 |
1967年 | 140篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Tetsuji Terazawa Takeshi Kato Masahiro Goto Katsuya Ohta Shingo Noura Hironaga Satake Yoshinori Kagawa Hisato Kawakami Hiroko Hasegawa Kazuhiro Yanagihara Tatsushi Shingai Ken Nakata Masahito Kotaka Masayuki Hiraki Ken Konishi Shiro Nakae Daisuke Sakai Yukinori Kurokawa Toshio Shimokawa Taroh Satoh 《The oncologist》2021,26(1):17-e47
Lessons Learned
- Panitumumab monotherapy showed favorable efficacy and feasibility in the treatment of frail or elderly patients with RAS wild‐type unresectable colorectal cancer.
- It is especially effective for left‐sided tumors; therefore, panitumumab as first‐line treatment could be an additional therapeutic option for frail elderly patients, particularly in those who are unsuitable for upfront oxaliplatin‐based or irinotecan‐based combination regimens.
2.
Kazuko Sakai Takayuki Takahama Mototsugu Shimokawa Koichi Azuma Masayuki Takeda Terufumi Kato Haruko Daga Isamu Okamoto Hiroaki Akamatsu Shunsuke Teraoka Akira Ono Tatsuo Ohira Toshihide Yokoyama Nobuyuki Yamamoto Kazuhiko Nakagawa Kazuto Nishio 《Molecular oncology》2021,15(1):126
The WJOG8815L phase II clinical study involves patients with non‐small cell lung cancer (NSCLC) that harbored the EGFR T790M mutation, which confers resistance to EGFR tyrosine kinase inhibitors (TKIs). The purpose of this study was to assess the predictive value of monitoring EGFR genomic alterations in circulating tumor DNA (ctDNA) from patients with NSCLC that undergo treatment with the third‐generation EGFR‐TKI osimertinib. Plasma samples of 52 patients harboring the EGFR T790M mutation were obtained pretreatment (Pre), on day 1 of treatment cycle 4 (C4) or cycle 9 (C9), and at diagnosis of disease progression or treatment discontinuation (PD/stop). CtDNA was screened for EGFR‐TKI‐sensitizing mutations, the EGFR T790M mutation, and other genomic alterations using the cobas EGFR Mutation Test v2 (cobas), droplet digital PCR (ddPCR), and targeted deep sequencing. Analysis of the sensitizing—and T790M—EGFR mutant fractions (MFs) was used to determine tumor mutational burden. Both MFs were found to decrease during treatment, whereas rebound of the sensitizing EGFR MF was observed at PD/stop, suggesting that osimertinib targeted both T790M mutation‐positive tumors and tumors with sensitizing EGFR mutations. Significant differences in the response rates and progression‐free survival were observed between the sensitizing EGFR MF‐high and sensitizing EGFR MF‐low groups (cutoff: median) at C4. In conclusion, ctDNA monitoring for sensitizing EGFR mutations at C4 is suitable for predicting the treatment outcomes in NSCLC patients receiving osimertinib (Clinical Trial Registration No.: UMIN000022076).
Abbreviations
- CIs
- confidence intervals
- ctDNA
- circulating tumor DNA
- ddPCR
- droplet digital PCR
- EGFR
- epidermal growth factor receptor
- MFs
- mutant fractions
- NGS
- next‐generation sequencing
- NSCLC
- non‐small cell lung cancer
- ORR
- overall response rate
- OS
- overall survival
- PD
- progressive disease
- PFS
- progression‐free survival
- PR
- partial response
- SD
- stable disease
- TKI
- tyrosine kinase inhibitor
3.
Takaki Shimizu Satoshi Kato Satoru Demura Kazuya Shinmura Noriaki Yokogawa Yuki Kurokawa Noritaka Yonezawa Norihiro Oku Ryo Kitagawa Makoto Handa Ryohei Annen Yoshiyuki Okamoto Hideki Murakami Hiroyuki Tsuchiya 《Journal of orthopaedic science》2021,26(3):327-331
BackgroundLocomotive syndrome is a condition of reduced mobility due to problems with locomotive organs. Although lumbar spinal canal stenosis is one of the major diseases constituting locomotive syndrome, only few studies have focused on the association between the two pathologies. We aimed to investigate the effect of surgery on lumbar spinal canal stenosis with respect to locomotive syndrome using various physical function tests, including locomotive syndrome risk tests, before and after surgery.MethodsClinical data of 101 consecutive patients (male = 46; female = 55; mean age, 69.3 years) who underwent surgery for lumbar spinal canal stenosis at our institute were prospectively collected. Results of physical function tests, including stand-up test, two-step test, and 25-Question Geriatric Locomotive Function Scale, and the sagittal vertical axis were evaluated before and 1 year after surgery. The association between several parameters and improvement of risk level in locomotive syndrome was evaluated.ResultsIn the total assessment, 93.1% of cases were in stage 2 and 6.9% in stage 1 preoperatively, while 72.4% were in stage 2, 22.4% in stage 1, and 5.2% in stage 0 at 1 year postoperatively. Postoperative improvement in the total assessment was observed in 28.7% of cases. Several physical function tests and sagittal vertical axis showed significant improvement after surgery. On multiple logistic regression analysis, age >75 years (odds ratio = 10.9, confidence interval = 1.09–109) and postoperative sagittal vertical axis >40 mm (odds ratio = 17.8, confidence interval = 1.78–177) were significant risk factors associated with non-improvement in risk level of locomotive syndrome.ConclusionsSurgical treatment for lumbar spinal canal stenosis improved physical function, including locomotive syndrome. Risk factors associated with non-improvement of locomotive syndrome were later-stage elderly and postoperative sagittal balance impairment. 相似文献
4.
5.
Introduction
Breast cancer incidence increases from the age of 30 years. As this age range coincides with that in which women usually pursue pregnancy, undergoing medical examinations for conditions such as breast cancer is a concern, especially when pregnancy is uncertain during the first eight weeks. Moreover, in this age range, breast often exhibits a high density, thus compromising diagnosis. For such density, digital breast tomosynthesis (DBT) provides a more accurate diagnosis than 2D mammography given its higher sensitivity and specificity. However, radiation exposure increases during DBT, and it should be determined.Methods
We determined the entrance surface dose, scattered radiation dose, and average glandular dose (AGD), which can be mutually compared following an international protocol. Using our proposed method, the distribution of scattered radiation can be easily and quickly obtained with a minor load to the equipment. Then, we can determine the indoor scattered radiation and surface dose on patients during DBT.Results
We obtained a maximum AGD of 2.32 mGy. The scattered radiation was distributed over both sides with maximum of approximately 40 μGy, whereas the maximum dose around the eye was approximately 10 μGy.Conclusion
By measuring doses using the proposed method, a correct dose information can be provided for patients to mitigate their concerns about radiation exposure. Although the obtained doses were low, their proper management is still required. Overall, the results from this study can help to enhance dose management for patients and safety management regarding indoor radiation. 相似文献6.
Abe Takashi Yabuuchi Akiko Ezoe Kenji Skaletsky Helen Fukuda Junichiro Ueno Satoshi Fan Yuting Goldsmith Sierra Kobayashi Tamotsu Silber Sherman Kato Keiichi 《Journal of assisted reproduction and genetics》2020,37(2):297-304
Journal of Assisted Reproduction and Genetics - To determine age-adjusted overall success rates for patients undergoing clomiphene citrate only minimal stimulation cycle (mini) in vitro... 相似文献
7.
Mamiko Onuki Koji Matsumoto Takashi Iwata Kasumi Yamamoto Yoichi Aoki Shoji Maenohara Naotake Tsuda Shoji Kamiura Kazuhiro Takehara Koji Horie Nobutaka Tasaka Hideaki Yahata Yuji Takei Yoichi Aoki Hisamori Kato Takeshi Motohara Keiichiro Nakamura Mitsuya Ishikawa Tatsuya Kato Hiroyuki Yoshida Noriomi Matsumura Hidekatsu Nakai Shogo Shigeta Fumiaki Takahashi Kiichiro Noda Nobuo Yaegashi Hiroyuki Yoshikawa 《Cancer science》2020,111(7):2546-2557
To obtain baseline data for cervical cancer prevention in Japan, we analyzed human papillomavirus (HPV) data from 5045 Japanese women aged less than 40 years and diagnosed with cervical abnormalities at 21 hospitals during 2012‐2017. These included cervical intraepithelial neoplasia grade 1 (CIN1, n = 573), CIN2‐3 (n = 3219), adenocarcinoma in situ (AIS, n = 123), and invasive cervical cancer (ICC, n = 1130). The Roche Linear Array was used for HPV genotyping. The HPV type‐specific relative contributions (RCs) were estimated by adding multiple infections to single types in accordance with proportional weighting attributions. Based on the comparison of type‐specific RCs between CIN1 and CIN2‐3/AIS/ICC (CIN2+), RC ratios were calculated to estimate type‐specific risks for progression to CIN2+. Human papillomavirus DNA was detected in 85.5% of CIN1, 95.7% of CIN2‐3/AIS, and 91.2% of ICC. Multiple infections decreased with disease severity: 42.9% in CIN1, 40.4% in CIN2‐3/AIS, and 23.7% in ICC (P < .0001). The relative risk for progression to CIN2+ was highest for HPV16 (RC ratio 3.78, 95% confidence interval [CI] 3.01‐4.98), followed by HPV31 (2.51, 1.54‐5.24), HPV18 (2.43, 1.59‐4.32), HPV35 (1.56, 0.43‐8.36), HPV33 (1.01, 0.49‐3.31), HPV52 (0.99, 0.76‐1.33), and HPV58 (0.97, 0.75‐1.32). The relative risk of disease progression was 1.87 (95% CI, 1.71‐2.05) for HPV16/18/31/33/35/45/52/58, but only 0.17 (95% CI, 0.14‐0.22) for HPV39/51/56/59/66/68. Human papillomavirus 16/18/31/33/45/52/58/6/11 included in a 9‐valent vaccine contributed to 89.7% (95% CI, 88.7‐90.7) of CIN2‐3/AIS and 93.8% (95% CI, 92.4‐95.3) of ICC. In conclusion, our data support the Japanese guidelines that recommend discriminating HPV16/18/31/33/35/45/52/58 genotypes for CIN management. The 9‐valent vaccine is estimated to provide over 90% protection against ICC in young Japanese women. 相似文献
8.
9.
10.
Left Atrial Appendage Flow Velocity and Time from P‐Wave Onset to Tissue Doppler–Derived A' Predict Atrial Fibrillation Recurrence after Radiofrequency Catheter Ablation 下载免费PDF全文
Keiko Fukushima M.D. Ph.D. Noritoshi Fukushima M.D. Ph.D. Koichiro Ejima M.D. Ph.D. Ken Kato M.D. Yasuto Sato Ph.D. Shoko Uematsu M.D. Kotaro Arai M.D. Ph.D. Tetsuyuki Manaka M.D. Ph.D. Atsushi Takagi M.D. Ph.D. Kyomi Ashihara M.D. Ph.D. Morio Shoda M.D. Ph.D. Nobuhisa Hagiwara M.D. Ph.D. 《Echocardiography (Mount Kisco, N.Y.)》2015,32(7):1101-1108